Clinical trial Recruiting at 1 site Interventional Ages 18 to 75

Using MRI to predict treatment success in lung cancer

Official title: Application of DCE-MRI Based on 4D FreeBreathing in Predicting the Efficacy of Immune and Targeted Therapy in Lung Cancer

Run by Yunnan Cancer Hospital · NCT06742021 · Data updated 2026-11-12

This study is testing if special MRI scans can help doctors better predict how well targeted and immunotherapy treatments will work for people with lung cancer.

Quick facts

Study typeInterventional
Ages18 Years to 75 Years
SexAll
Enrollment195 (estimated)
SponsorYunnan Cancer Hospital
Academic / other
Drugs / interventionsimmunotherapy
Locations1 site (Kunming, Yunnan)
StatusRecruiting
StartedNovember 11, 2024
Main results expectedJuly 31, 2026
Study endsJuly 31, 2026
Registry record updatedDecember 19, 2024
Trial IDNCT06742021 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are lung cancer patients aged 18 to 75 with tumors larger than 2 cm.

Probably not a fit

Patients with MRI contraindications or those who cannot tolerate gadolinium contrast agents may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to improve the prediction of treatment efficacy for lung cancer patients undergoing targeted and immunotherapy. It utilizes dynamic contrast-enhanced MRI (DCE-MRI) images taken before and after the first treatment cycle, combined with clinical and pathological data, to assess how well these therapies work. By analyzing these images, the study seeks to provide more accurate predictions that could guide treatment decisions for patients with lung cancer.

Why it matters

Potential benefit: If successful, this approach could lead to more personalized and effective treatment plans for lung cancer patients.

How similar studies have gone: While the use of MRI in treatment prediction is explored, this specific approach utilizing DCE-MRI in lung cancer is relatively novel.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

1. Tumor size greater than 2 cm
2. Age between 18 and 75 years

Exclusion Criteria:

1. Presence of MRI contraindications (e.g., metal implants, pacemaker implantation, etc.)
2. Allergy to gadolinium contrast agents
3. Lesions difficult to delineate on images due to conditions such as atelectasis or diffuse lesions

Where it's running

  • Yunnan Cancer Hospital
    Kunming, Yunnan, China
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.